undamentalytics Newsletter
Sign in

Ironwood Pharmaceuticals Inc cash flow statement

In fiscal 2025, Ironwood Pharmaceuticals Inc's operations generated $127m of cash; it spent $34,000 on capital projects, leaving free cash flow of $127m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−3−68−75−70−273−156−107−26−101−7111169262274183104127186
Depreciation and amortisation561011121212106462211111
Stock-based pay5712182026252931413131222732301714
Capital spending4171014104443072000000
Free cash flow−7−85−85−84−283−159−111−30−104−714167262274183103127186
Free cash flow after stock pay−12−93−97−101−303−185−136−59−134−112−2813623924715174110171
Share buybacks————————————24126————
Shares issued———85138190————————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: INVA vs IRWDIRWD vs XERSEOLS vs IRWD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Ironwood Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ironwood Pharmaceuticals Inc.